-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Life science is a science that studies various forms of life, covering immunology, molecular biology, cell biology, genetics, medicine, pharmacy, biochemistry and many other fields, so it is related to human health, economic construction and society.
Development and other aspects are closely related
.
In recent years, with the gradual increase in national scientific research investment, the life science industry has ushered in rapid development
.
Data shows that China's research and experiment (R&D) funding has increased from 706.
3 billion yuan in 2010 to 217.
3 billion yuan in 2019, with an average annual compound growth rate of 13.
30%
.
In the context of the rapid development of the life science industry, its upstream industry chain, including related equipment, consumables, raw materials and services, has also ushered in a large increase in demand
.
In the field of biomedicine, according to statistics from EMERGEN RESEARCH, the scale of biomedicine production-related industries in 2020 is about 18.
3 billion U.
S.
dollars, which mainly involve pharmaceutical equipment, raw materials and consumables
.
Pharmaceutical equipment is the "mother machine" of pharmaceutical production, which directly affects the level of pharmaceutical production and product quality
.
Although China's pharmaceutical equipment industry started late, it has developed rapidly in the past 10 years and the market scale has continued to expand, from 156 yuan in 2010 to 35.
87 billion yuan in 2020
.
The main reason is that, on the one hand, affected by the 2010 version of GMP certification, the pharmaceutical equipment industry is accelerating the update and upgrading and ushering in demand growth; on the other hand, under the policies of centralized procurement and consistency evaluation, the pharmaceutical industry has also accelerated its transformation in recent years.
With the rapid development of upstream and downstream biomedicine, the pharmaceutical equipment industry has obtained a new round of development opportunities
.
The current pace of development in the field of biomedicine is accelerating, and new technologies and new drugs are emerging one after another.
The industry infers that in the research phase, biological reagents, consumables, and experimental equipment will also usher in a large amount of demand
.
However, in the process development and production stage of biopharmaceuticals, due to the complex process and high degree of specialization, it also requires a large amount of media preparation, seed cultivation, scale up, fermentation production, separation, purification, filtration, and filling.
Support of professional equipment, raw materials and consumables
.
In this context, it is expected that the pharmaceutical equipment market will continue to grow in the future.
China's pharmaceutical equipment market will reach 40 billion yuan in 2021, and it will further approach the 45 billion yuan mark in 2022
.
What needs to be noticed is that at present, whether it is biological laboratory consumables or biopharmaceutical equipment, the domestic market, especially the high-end market, is still dominated by imported products.
The domestic equipment is generally stuck in the neck, compared with European, American, Japanese and other equipment.
Obvious gaps, and in terms of corporate strength, domestic equipment companies also need to be improved in terms of product design capabilities, raw material performance, and quality inspection levels
.
The development of domestic high-end pharmaceutical equipment and the acceleration of domestic substitution are being supported by policies and other aspects
.
The industry believes that they should have confidence in domestic pharmaceutical equipment companies
.
With the release of favorable policies and the increase in the capital market, some domestic pharmaceutical companies are expected to achieve new breakthroughs in product performance and quality, gradually breaking the import monopoly, creating high-end consumables and high-end biopharmaceutical equipment brands, and helping China's biopharmaceutical industry to stabilize for a long time.
Healthy development
.
In recent years, it can be seen that, consistent with the M&A strategy adopted by the international leading companies in the development, Chutian Technology, one of the domestic pharmaceutical equipment companies, has acquired the German pharmaceutical equipment giant ROMACO through a huge amount, thereby enhancing its brand influence and accelerating internationalization.
Business expansion may be able to gain market share and top position in market segments relatively quickly in the future
.
Development and other aspects are closely related
.
In recent years, with the gradual increase in national scientific research investment, the life science industry has ushered in rapid development
.
Data shows that China's research and experiment (R&D) funding has increased from 706.
3 billion yuan in 2010 to 217.
3 billion yuan in 2019, with an average annual compound growth rate of 13.
30%
.
In the context of the rapid development of the life science industry, its upstream industry chain, including related equipment, consumables, raw materials and services, has also ushered in a large increase in demand
.
In the field of biomedicine, according to statistics from EMERGEN RESEARCH, the scale of biomedicine production-related industries in 2020 is about 18.
3 billion U.
S.
dollars, which mainly involve pharmaceutical equipment, raw materials and consumables
.
Pharmaceutical equipment is the "mother machine" of pharmaceutical production, which directly affects the level of pharmaceutical production and product quality
.
Although China's pharmaceutical equipment industry started late, it has developed rapidly in the past 10 years and the market scale has continued to expand, from 156 yuan in 2010 to 35.
87 billion yuan in 2020
.
The main reason is that, on the one hand, affected by the 2010 version of GMP certification, the pharmaceutical equipment industry is accelerating the update and upgrading and ushering in demand growth; on the other hand, under the policies of centralized procurement and consistency evaluation, the pharmaceutical industry has also accelerated its transformation in recent years.
With the rapid development of upstream and downstream biomedicine, the pharmaceutical equipment industry has obtained a new round of development opportunities
.
The current pace of development in the field of biomedicine is accelerating, and new technologies and new drugs are emerging one after another.
The industry infers that in the research phase, biological reagents, consumables, and experimental equipment will also usher in a large amount of demand
.
However, in the process development and production stage of biopharmaceuticals, due to the complex process and high degree of specialization, it also requires a large amount of media preparation, seed cultivation, scale up, fermentation production, separation, purification, filtration, and filling.
Support of professional equipment, raw materials and consumables
.
In this context, it is expected that the pharmaceutical equipment market will continue to grow in the future.
China's pharmaceutical equipment market will reach 40 billion yuan in 2021, and it will further approach the 45 billion yuan mark in 2022
.
What needs to be noticed is that at present, whether it is biological laboratory consumables or biopharmaceutical equipment, the domestic market, especially the high-end market, is still dominated by imported products.
The domestic equipment is generally stuck in the neck, compared with European, American, Japanese and other equipment.
Obvious gaps, and in terms of corporate strength, domestic equipment companies also need to be improved in terms of product design capabilities, raw material performance, and quality inspection levels
.
The development of domestic high-end pharmaceutical equipment and the acceleration of domestic substitution are being supported by policies and other aspects
.
The industry believes that they should have confidence in domestic pharmaceutical equipment companies
.
With the release of favorable policies and the increase in the capital market, some domestic pharmaceutical companies are expected to achieve new breakthroughs in product performance and quality, gradually breaking the import monopoly, creating high-end consumables and high-end biopharmaceutical equipment brands, and helping China's biopharmaceutical industry to stabilize for a long time.
Healthy development
.
In recent years, it can be seen that, consistent with the M&A strategy adopted by the international leading companies in the development, Chutian Technology, one of the domestic pharmaceutical equipment companies, has acquired the German pharmaceutical equipment giant ROMACO through a huge amount, thereby enhancing its brand influence and accelerating internationalization.
Business expansion may be able to gain market share and top position in market segments relatively quickly in the future
.
